{
    "clinical_study": {
        "@rank": "163003", 
        "arm_group": {
            "arm_group_label": "Abiraterone Acetate", 
            "arm_group_type": "Experimental", 
            "description": "Abiraterone acetate 1000mg orally daily until the time of disease progression, in the absence of prohibitive toxicities."
        }, 
        "brief_summary": {
            "textblock": "This is a pilot study of abiraterone acetate in African American/Black patients with\n      castration-resistant prostate cancer.  The primary objective is to determine the correlation\n      between germline polymorphisms and antitumor activity (as defined by a decline in PSA of \u2265\n      30%) in African American patients with castration-resistant prostate cancer treated with\n      abiraterone acetate. Patients will receive abiraterone acetate until the time of disease\n      progression, in the absence of prohibitive toxicities. Patients will be followed for disease\n      progression and survival."
        }, 
        "brief_title": "Abiraterone Acetate Trial in African American Prostate Cancer Patients", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Have signed an informed consent document indicating that the subjects understands\n             the purpose of and procedures required for the study and are willing to participate\n             in the study\n\n          -  Be willing/able to adhere to the prohibitions and restrictions specified in this\n             protocol\n\n          -  Written Authorization for Use and Release of Health and Research Study Information\n\n          -  African American or Black (by self identification)\n\n          -  Male aged 18 years and above\n\n          -  Histologically or cytologically confirmed adenocarcinoma of the prostate\n\n          -  Metastatic disease documented by standard imaging\n\n          -  Progressive prostate cancer based on either rising PSA, new bone metastases, or\n             progression of measurable disease according to PCWG2 12 guidelines.\n\n          -  Patients in either of the following clinical states will be eligible for enrollment:\n\n             i. No prior chemotherapy; ii. Patients previously treated with 1-2 prior chemotherapy\n             regimens permitted, one of which must have been included docetaxel\n\n          -  Surgically or medically castrated, with testosterone levels of < 50 ng/dl.\n\n          -  Patients previously treated with an anti-androgen must demonstrate progression off of\n             the anti-androgen.\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of \u2264 2\n\n          -  Have a baseline serum potassium of \u2265 3.5 mEq/L\n\n          -  Have aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin\n             levels < 1.5 x ULN\n\n          -  Have a serum albumin of \u2265 3.0 g/dL\n\n          -  Total bilirubin \u2264 1.5 x ULN\n\n          -  Have a platelet count of \u2265 100,000/\u03bcL\n\n          -  Have an absolute neutrophil count of > 1500 cell/mm3\n\n          -  Have a calculated creatinine clearance \u2265 60 mL/min\n\n          -  Have a hemoglobin of \u2265 9.0 g/dL\n\n          -  Able to swallow the study drug as a whole tablet\n\n          -  Willing to take abiraterone acetate on an empty stomach; no food should be consumed\n             at least two hours before and for at least one hour after the dose of abiraterone\n             acetate is taken\n\n          -  Patients who have partners of childbearing potential must be willing to use a method\n             of birth control with adequate barrier protection as determined to be acceptable by\n             the principal investigator during the study and for 1 week after last dose of\n             abiraterone acetate\n\n        Exclusion Criteria:\n\n          -  Active infection or other medical condition that would make prednisone/prednisolone\n             (corticosteroid) use contraindicated\n\n          -  Known brain metastasis\n\n          -  Uncontrolled hypertension (systolic BP \u2265 160 mmHg or diastolic BP \u2265 95 mmHg) Patients\n             with a history of hypertension are allowed provided blood pressure is controlled by\n             anti-hypertensive treatment\n\n          -  Active or symptomatic viral hepatitis or chronic liver disease\n\n          -  History of pituitary or adrenal dysfunction\n\n          -  Clinically significant heart disease as evidenced by myocardial infarction, or\n             arterial thrombotic events in the past 6 months, severe or unstable angina, or New\n             York Heart Association (NYHA) Class III-IV heart disease or cardiac ejection fraction\n             measurement of < 50% at baseline\n\n          -  Administration of an investigational therapeutic within 30 days of  screening\n\n          -  Have any condition that, in the opinion of the investigator, would compromise the\n             well-being of the subject or the study or prevent the subject from meeting or\n             performing study requirements\n\n          -  Have poorly controlled diabetes\n\n          -  Have a history of gastrointestinal disorders (medical disorders or extensive surgery)\n             that may interfere with the absorption of the study agents\n\n          -  Have a pre-existing condition that warrants long-term corticosteroid use in excess of\n             study dose\n\n          -  Have known allergies, hypersensitivity, or intolerance to abiraterone acetate or\n             prednisone or their excipients"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01735396", 
            "org_study_id": "GCO 12-1727"
        }, 
        "intervention": {
            "arm_group_label": "Abiraterone Acetate", 
            "description": "Abiraterone acetate 1000 mg orally daily (supplied as four 250 mg tablets) and prednisone 5 mg orally twice daily", 
            "intervention_name": "Abiraterone Acetate", 
            "intervention_type": "Drug", 
            "other_name": "Zytiga"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "African American men", 
            "metastatic prostate cancer", 
            "castration resistant"
        ], 
        "lastchanged_date": "November 26, 2013", 
        "link": {
            "description": "Mt. Sinai Tisch Cancer Institute", 
            "url": "http://www.mssm.edu/research/institutes/tisch-cancer-institute"
        }, 
        "location": [
            {
                "contact": {
                    "email": "matthew.galsky@mssm.edu", 
                    "last_name": "Matthew Galsky, MD", 
                    "phone": "212-824-8587"
                }, 
                "contact_backup": {
                    "email": "william.oh@mssm.edu", 
                    "last_name": "William Oh, MD", 
                    "phone": "212-659-5549"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029"
                    }, 
                    "name": "Icahn School of Medicine at Mount Sinai"
                }, 
                "investigator": {
                    "last_name": "Matthew Galsky, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kemenym@nychhc.org", 
                    "last_name": "Margaret Kemeny, MD", 
                    "phone": "718-883-4031"
                }, 
                "contact_backup": {
                    "email": "courtney.phillips@mountsinai.org", 
                    "last_name": "Courtney Philips, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11432"
                    }, 
                    "name": "Queens Cancer Center, Queens Hospital"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study of Abiraterone Acetate in African American/Black Patients With Castration Resistant Prostate Cancer", 
        "overall_contact": {
            "email": "matthew.galsky@mssm.edu", 
            "last_name": "Matthew Galsky, MD", 
            "phone": "212-824-8587"
        }, 
        "overall_official": {
            "affiliation": "Mount Sinai School of Medicine", 
            "last_name": "Matthew Galsky, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of this study is to determine a correlation between inherited genetic polymorphisms and antitumor activity (as defined by a decline in PSA of \u2265 30%) in AA patients with castration-resistant prostate cancer treated with Abiraterone. The primary endpoint is the percent change in PSA from baseline to 12 weeks. A decline of \u2265 30% will be correlated with germline SNPs.", 
            "measure": "The percent change in PSA", 
            "safety_issue": "No", 
            "time_frame": "baseline and 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01735396"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mount Sinai School of Medicine", 
            "investigator_full_name": "Matthew Galsky", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine the time to progression (as per PCWG2 guidelines)\nPost-treatment changes in measurable disease (as per PCWG2 guidelines)", 
                "measure": "Time to progression", 
                "safety_issue": "Yes", 
                "time_frame": "up to 12 weeks"
            }, 
            {
                "description": "To determine post-treatment changes in measurable disease by RECIST", 
                "measure": "RECIST", 
                "safety_issue": "Yes", 
                "time_frame": "up to 12 weeks"
            }, 
            {
                "description": "To determine post-treatment changes in bone scans (as per PCWG2 guidelines) (\"no new lesions\" versus \"new lesions.\")", 
                "measure": "bone scan", 
                "safety_issue": "Yes", 
                "time_frame": "up to 12 weeks"
            }, 
            {
                "description": "To determine the safety of abiraterone Adverse events as defined by CTCAE v4", 
                "measure": "safety of abiraterone", 
                "safety_issue": "Yes", 
                "time_frame": "up to 12 weeks"
            }, 
            {
                "description": "Post-treatment changes in testosterone", 
                "measure": "Testosterone", 
                "safety_issue": "Yes", 
                "time_frame": "up to 12 weeks"
            }
        ], 
        "source": "Mount Sinai School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mount Sinai School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}